Serious Safety Concerns Associated With Saxenda Severe Gastrointestinal Motility Disorders Reported injuries include: gastroparesis (stomach paralysis) ileus (functional bowel shutdown) severe constipation chronic digestive dysfunction Related: Motility Disorders Dehydration & Kidney Injury Ongoing vomiting or reduced intake may lead to: dehydration electrolyte imbalance acute kidney injury (AKI) worsening kidney disease Related: Dehydration and Kidney Damage Gallbladder Disease Weight loss and altered bile flow may increase the risk of: gallstones gallbladder inflammation gallbladder removal surgery Related: Gallbladder Removal Pancreatitis Some patients report: severe abdominal pain elevated pancreatic enzymes hospitalization for pancreatitis Related: Pancreatitis Vision Problems / NAION Serious vision complications, including Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) , have been reported across the GLP-1 drug class
Remove the cap(s) from the pen
It's important to contextualize this concern: No published study has shown BPC-157 causing or promoting tumor growth The body already produces BPC-157-related compounds naturally in gastric juice Many foods and supplements (such as curcumin and certain vitamins) also promote angiogenesis without being considered cancer risks The concern remains theoretical, not evidence-based, but it warrants continued research Out of an abundance of caution, we recommend that individuals with active malignancies consult their oncologist before using BPC-157
His expertise spans healthcare, technology, and mineral exploration
Currently, Poxel is working with Metavant, a subsidiary of Roivant Sciences, to advance imeglimin into a phase III project
